Show simple item record

dc.contributor.authorHaywood, Alisonen_US
dc.contributor.authorV, Llewelynen_US
dc.contributor.authorS, Robertsonen_US
dc.contributor.authorM, Mylreaen_US
dc.contributor.authorB, Glassen_US
dc.contributor.editorMoyez Jiwaen_US
dc.date.accessioned2017-05-03T14:23:21Z
dc.date.available2017-05-03T14:23:21Z
dc.date.issued2011en_US
dc.date.modified2014-10-09T00:54:53Z
dc.identifier.issn18361935en_US
dc.identifier.doi10.4066/AMJ.2011.693en_US
dc.identifier.urihttp://hdl.handle.net/10072/41895
dc.description.abstractDose administration aid (DAA) usage has become increasingly prevalent among populations worldwide and as such has become an important part of pharmacy practice. The evidence for the use of these aids has been favourable in Australia resulting in 2006 in a community based DAA program being considered by the Professional Programs and Services Advisory Committee and the first phase of this program implemented in October 2007. The program was established under the Better Community Health Initiative of the 4th Community Pharmacy Agreement with the Government. The aim of this program is to reduce medication-related hospitalizations and adverse events through improved medication management and adherence for people in the community. The most common patient groups that access this service include the elderly, who are often on several different medications and patients with cognitive disabilities who may have trouble understanding or remembering their dosage regimes. Repackaging of a medication, involving removal from its primary packaging invalidates the stability guarantee of the manufacturer. It is in fact the role of the health team to ensure patient care by making an informed judgment as to the effect on the quality and safety of this repackaging process. Drug manufacturers, on the whole, tend to discourage repackaging of medications and as there is little quality data available to support this process. Indeed, only a small number of medications have been investigated for their stability following repackaging into DAAs, namely atenolol, paracetamol, frusemide, prochlorperazine, sodium valproate, aspirin (dosette boxes) and clozapine. This paper will review the repackaging of medications into DAAs and the role that the pharmacist plays in this process to improve patient care, in addition to presenting the Australian research that has contributed substantially to the body of information available internationally on the quality implications, relating to the stability of repackaging medicines into DAAs.en_US
dc.description.peerreviewedYesen_US
dc.description.publicationstatusYesen_US
dc.format.extent567485 bytes
dc.format.mimetypeapplication/pdf
dc.languageEnglishen_US
dc.language.isoen_US
dc.publisherAustralasian Medical Journal Pty. Ltd.en_US
dc.publisher.placeAustraliaen_US
dc.relation.ispartofstudentpublicationNen_US
dc.relation.ispartofpagefrom183en_US
dc.relation.ispartofpageto189en_US
dc.relation.ispartofissue4en_US
dc.relation.ispartofjournalAustralasian Medical Journalen_US
dc.relation.ispartofvolume4en_US
dc.rights.retentionYen_US
dc.subject.fieldofresearchPharmaceutical Sciencesen_US
dc.subject.fieldofresearchcode111504en_US
dc.titleDose Administration Aids: Pharmacists' Role in Improving Patient Careen_US
dc.typeJournal articleen_US
dc.type.descriptionC1 - Peer Reviewed (HERDC)en_US
dc.type.codeC - Journal Articlesen_US
gro.facultyGriffith Health, School of Pharmacyen_US
gro.rights.copyrightCopyright remains with the authors 2011. The attached file is reproduced here in accordance with the copyright policy of the publisher. For information about this journal please refer to the journal's website or contact the authors.en_US
gro.date.issued2011
gro.hasfulltextFull Text


Files in this item

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record